- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04368507
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients
A Phase 1b/2a Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab) in Combination With Irinotecan in Metastatic or Recurrent Colorectal Cancer Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Korea, Republic of, 06351
- Samsung Medical Center
-
-
Goyang-si, Gyeonggi-do
-
Seoul, Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
- National Cancer Center
-
-
Seocho-gu
-
Seoul, Seocho-gu, Korea, Republic of, 06591
- Seoul st. mary's hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients aged ≥ 19 years
Patients with histologically confirmed metastatic or recurrent colorectal cancer
- Patients who progressed after standard anticancer treatment including existing fluoropyrimidine, oxaliplatin, and irinotecan
- Patients who received anticancer treatment including irinotecan for at least 6 weeks, with progression confirmed radiologically while on anticancer treatment or within 6 months (24 weeks) after completion of anticancer treatment
- Adjuvant therapy is acknowledged as an anticancer therapy, if PD is confirmed within 6 months (24 weeks) after the last dose
- Patients who are unable to undergo radical resection 3) Patients with Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 4) Patients with life expectancy of at least 12 weeks 5) Patients with confirmed adequate hematologic, renal and hepatic function based on the following criteria:
- ANC ≥ 1,500/μL (without granulocyte colony-stimulating factor (G-CSF) administration within 2 weeks prior to baseline)
- Platelet ≥ 100,000/μL (without transfusion within 2 weeks prior to baseline)
- Hemoglobin ≥ 9 g/dL (without transfusion within 4 weeks prior to baseline)
- Serum creatinine ≤ 1.5 mg/dL or estimated glomerular filtration rate (eGFR) (or GFR) ≥ 60 mL/min/1.73 m2
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST and ALT ≤ 5 X ULN for subjects with confirmed hepatic metastases)
- Total bilirubin ≤ 1.5 X ULN
- Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN
- Urine protein to creatinine ratio (UPC) < 1.0 0 (g/g)a a UPC will be conducted only when urine dipstick protein level is ≥ 1 positive (+).
6. Patients with a measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 7. Patients who voluntarily agree to participate in the study and sign the informed consent form
Exclusion Criteria:
- Patients with hematologic malignancy including lymphoma
- Patients who received chemotherapy, biological therapy, immunotherapy (including immune checkpoint inhibitors), or radiotherapy within 4 weeks prior to baseline for the treatment of metastatic or recurrent colorectal cancer (Participation is not allowed if nitrosoureas or mitomycin is administered within 6 weeks prior to baseline or if biological target antibody is administered within 8 weeks prior to baseline)
Patients with a history of primary malignancy other than colorectal cancer. However, the patients are permitted to participate if:
- They have not received any treatment for the tumor or are disease-free for at least 5 years (For papillary carcinoma of thyroid, participation in the study is allowed even if it has not been more than 5 years after radical resection.)
- At least 1 year has passed since complete resection of basal/squamous cell carcinoma of the skin or successful treatment of cervical carcinoma in situ
- Patients with symptomatic central nervous system metastases (except for patients who have discontinued systemic corticosteroid treatment at least 4 weeks prior to baseline and are neurologically stable for at least 4 weeks)
Patients with the following medical or surgical/procedural history
- Deep vein thrombosis (DVT) or pulmonary embolism (PE) within 1 year prior to baseline
- History of infection with cytomegalovirus (CMV) or Epstein-Barr virus (EBV) within 6 months (24 weeks) prior to baseline
- History of acute coronary syndrome (unstable angina or myocardial infarction) within 6 months (24 weeks) prior to baseline
- Serious cerebrovascular disease such as stroke within 6 months (24 weeks) prior to baseline
- Major surgery that requires general anesthesia or a ventilation assist within 4 weeks prior to baseline (within 2 weeks for video-assisted thoracoscopic surgery [VATS] or open-and-closed [ONC] surgery)
Patients with any of the following diseases:
- New York Heart Association (NYHA) class III or IV heart failure
- Uncontrolled hypertension (SBP > 160 mmHg or DBP > 90 mmHg despite drug treatments)
- Clinically significant cardiovascular abnormalities as determined by the investigator (e.g., left ventricular ejection fraction [LVEF] < 50%, clinically significant abnormal cardiac wall or myocardial injury, or uncontrolled cardiac arrhythmias)
- Known positive human immunodeficiency virus (HIV)
- Severe infection requiring systemic antibiotics, antivirals, etc. or other uncontrolled acute active infectious diseases
- Chronic inflammatory bowel disease
- Severe enteroplegia or ileus requiring intervention
- Pneumonitis or pulmonary fibrosis
- Large amount of ascites or pleural fluid
- Diarrhea (watery stool)
- Patients requiring continued treatment with systemic corticosteroids
- Patients on antithrombotic agents (patients on low dose aspirin of < 325 mg for inhibition of platelet aggregation is allowed to participate) or with a predisposition to bleeding, large amount of hemoptysis, gastrointestinal hemorrhage or peptic ulcers
- Patients with a history of severe drug hypersensitivity or hypersensitivity to class of drugs similar to the study drug/concurrent medications
- Pregnant or breast-feeding women
- Women of childbearing potential and men who are unwilling to remain abstinent or use appropriate methods of contraception during the study and for at least 5 months (20 weeks) following the end of treatment
- Patients who received other investigational product or used any investigational device within 4 weeks prior to baseline
- Patients considered ineligible to participate in the clinical study according to the investigator's judgement for other reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: YYB101+Irinotecan
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1b (Dose level 0) cohort: Safety, Tolerability of YYB101 by DLTs and MTD
Time Frame: 28 days
|
DLTs and MTD
|
28 days
|
2a cohort: Safety, Tolerability of YYB101 by ORR
Time Frame: By 12 months after enrollment of the last subject
|
ORR
|
By 12 months after enrollment of the last subject
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1b (Dose level 0) cohort
Time Frame: By 12 months after enrollment of the last subject
|
Safety and tolerability (MTD/RP2D based by DLT, Incidence of AEs that result in discontinuation and dose reduction of YYB101, Clinical laboratory abnormalities that result in discontinuation and dose reduction of YYB101, Vital sign that result in discontinuation and dose reduction of YYB101, Anti-YYB101 antibody that result in discontinuation and dose reduction of YYB101)
|
By 12 months after enrollment of the last subject
|
1b (Dose level 0) cohort
Time Frame: By 12 months after enrollment of the last subject
|
Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)
|
By 12 months after enrollment of the last subject
|
1b (Dose level 0) cohort
Time Frame: By 12 months after enrollment of the last subject
|
Pharmacokinetics: Peak Plasma Concentration (Cmax)
|
By 12 months after enrollment of the last subject
|
1b (Dose level 0) cohort
Time Frame: By 12 months after enrollment of the last subject
|
Pharmacokinetics: Serum HGF Concentration profile
|
By 12 months after enrollment of the last subject
|
1b (Dose level 0) cohort
Time Frame: By 12 months after enrollment of the last subject
|
Antitumor activity of YYB101 and Irinotecan (Tumor response result evaluted by RECIST version 1.1)
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Progression-free survival (PFS) will be measured using RECIST version 1.1
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Disease Control Rate (DCR) will be measured using RECIST version 1.1
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Duration Of Response (DOR) will be measured using RECIST version 1.1
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Overall Survival (OS) will be measured using RECIST version 1.1
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Safety profile (Incidence of AEs that result in discontinuation and dose reduction of YYB101, Clinical laboratory abnormalities that result in discontinuation and dose reduction of YYB101, Vital sign that result in discontinuation and dose reduction of YYB101, Anti-YYB101 antibody that result in discontinuation and dose reduction of YYB101)
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Pharmacokinetics: Peak Plasma Concentration (Cmax)
|
By 12 months after enrollment of the last subject
|
2a cohort
Time Frame: By 12 months after enrollment of the last subject
|
Pharmacokinetics: Serum HGF Concentration profile [only stage 1 subject]
|
By 12 months after enrollment of the last subject
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Hoonkyo Kim, Ph.D, National OncoVenture/National Cancer Center
- Study Director: Garam Im, National OncoVenture/National Cancer Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Recurrence
- Antineoplastic Agents
- Monoclonal antibody YYB-101
Other Study ID Numbers
- NOV110501-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer Metastatic
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on YYB101
-
CellabMEDCompletedSolid TumorsKorea, Republic of
-
University of WaterlooAdvanced Vision ResearchCompleted